Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)

NCT04790708 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

250

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors
Peptide Receptor Radionuclide Therapy (PRRT)

Interventions

RADIATION: Lutetium-177 (177Lu)-DOTATOC
RADIATION: Yttrium-90 (90Y)-DOTATOC
RADIATION: 177Lu-DOTATOC + 90Y-DOTATOC
RADIATION: Re-treatment 177Lu-DOTATOC
RADIATION: Re-treatment 90Y-DOTATOC

Sponsor

University Hospital of Ferrara